Abstract: Objective: To investigate the efficacy and safety of oral propranolol in the treatment of high-risk infantile hemangiomas. Methods: Retrospective analysis of the clinical data of 81 infants with high-risk hemangiomas treated with oral propranolol from March 2018 to January 2024, evaluating the treatment efficacy and safety. Results: The mean age of the first diagnosis of 81 children was 3 months, and the efficacy was evaluated after 6 months of treatment with propranolol. Efficacy of 96 hemangiomas in 81 patients were grade I of 12 lesions, grade II of 12 lesions, grade III of 20 lesions, grade IV of 52 lesions. The effective rate (grade III + grade IV) was 75%. The therapeutic effect of patients with the initial age of ≤6 months was better than that of patients with the initial age of > 6 months (P<0.05). The effect of long-term treatment was better than that of short-term treatment (P<0.001). However, there was no significant difference in the treatment effect of infantile hemangiomas in different locations (P>0.05). No obvious serious adverse reactions occurred and the treatment effect was still satisfactory after recurrence. Conclusion: Oral propranolol is safe, effective and well tolerated in the treatment of high-risk infantile hemangiomas.

Key words: infantile hemangioma, high-risk, propranolol, efficacy